Why the study?
Does the measurement of systolic longitudinal myocardial strain and ultrasensitive troponin I predict subsequent cardiotoxicity in patients with breast cancer treated with anthracyclines, taxanes, and trastuzumab?
Does the measurement of systolic longitudinal myocardial strain and ultrasensitive troponin I predict subsequent cardiotoxicity in patients with breast cancer treated with anthracyclines, taxanes, and trastuzumab?
Systolic longitudinal myocardial strain and ultrasensitive troponin I can help predict and potentially avoid subsequent cardiotoxicity in breast cancer patients undergoing cardiotoxic chemotherapy.
May aid post-anthracycline risk stratification in breast cancer; leaves open prospective validation before routine surveillance changes.
In patients with breast cancer treated with anthracyclines, taxanes, and trastuzumab, systolic longitudinal myocardial strain and ultrasensitive troponin I measured at the completion of anthracyclines therapy are useful in the prediction of subsequent cardiotoxicity and may help guide treatment to avoid cardiac side-effects.
No takes yet. Share an insight, caveat, or question.
Sawaya et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: